SFO
TARO

Stokes Family Office’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Stokes Family Office’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,750
Closed -$286K – 338
2023
Q1 		$286K Buy
11,750
+1,150
+11% +$33.5K 0.04% 228
2022
Q4 		$308K Buy
+10,600
New +$314K 0.04% 214

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Stokes Family Office's TARO Position: Q2 2023 in Review

Stokes Family Office sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2023, closing a stake of 11,750 shares — an estimated $286K sold.

Stokes Family Office first reported a position in TARO in Q4 2022 and held it in 2 quarters. The position peaked at $308K in Q4 2022. 71 funds tracked by Wall St. Rank hold TARO as of Q2 2023.

  • Stokes Family Office reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2023 after selling out during the quarter.
  • Stokes Family Office sold 11,750 Taro Pharmaceutical Industries Ltd. shares in Q2 2023, an estimated $286K.
  • Stokes Family Office first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2022 and held it in 2 quarters.
  • Stokes Family Office's Taro Pharmaceutical Industries Ltd. position peaked at $308K in Q4 2022.
  • 71 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2023.

Based on Stokes Family Office's 13F filing for Q2 2023, filed 14 Aug 2023.